Jan J.-Y.SHIN-YU LINLin C.-H.CHIEN-NAN LEESHOU-ZEN FANYIN-YI HAN2020-09-292020-09-2920111341-8076https://scholars.lib.ntu.edu.tw/handle/123456789/515629Massive postpartum hemorrhage is one of the major complications in the peripartum period. In some critical cases, hemostasis is hard to achieve even after a hysterectomy has been performed. Recombinant activated factor VII has been reported as a promising adjuvant therapy for obstetric hemorrhage, although it remains unlicensed for this indication. Eight cases receiving recombinant activated factor VII in postpartum hemorrhage refractory to the conventional therapy in a Taiwanese hospital were analyzed retrospectively. A good response, defined as bleeding control in 15 min, was achieved in six patients (75%) with a single dose ranging from 55 to 105 μg/kg. The two patients with a poor response were later discovered to have had unsolved birth canal injuries. No drug-related adverse effects were noted. We recommend that any surgical bleeding should first be controlled, as well as the correction of metabolic and hematological abnormalities; however, in the situation of intractable postpartum hemorrhage, recombinant activated factor VII offers a salvage therapy and should be considered early, even before hysterectomy. ? 2011 The Authors.[SDGs]SDG3fresh frozen plasma; methylergometrine; oxytocin; recombinant blood clotting factor 7a; absence of side effects; article; bleeding; chorioamnionitis; clinical article; disease control; disseminated intravascular clotting; drug indication; erythrocyte transfusion; female; human; hysterectomy; maternal morbidity; maternal mortality; medical practice; medical record review; obstetric anesthesia; placenta accreta; postoperative period; postpartum hemorrhage; repeated drug dose; retrospective study; salvage therapy; single drug dose; Taiwan; thrombocyte transfusion; treatment response; university hospital; uterine atony; vaginal delivery; Adult; Anesthesia, Obstetrical; Drug Resistance; Factor VIIa; Hemostatics; Hospitals, University; Humans; Male; Off-Label Use; Postpartum Hemorrhage; Recombinant Proteins; Retrospective Studies; Salvage Therapy; Taiwan; Time Factors; Young Adultjournal article10.1111/j.1447-0756.2010.01422.x217366692-s2.0-80052784040